The current COVID-19 pandemic, caused by the SARS-CoV-2 virus, represents a major threat to health. The COVID-19 Genomics UK (COG-UK) Consortium has been created to deliver large-scale and rapid whole-genome virus sequencing to local NHS centres and the UK government. Its data will help Public Health Agencies to manage the COVID-19 outbreak in the UK and inform vaccine research efforts.

The Goal

The goal of the COG-UK Consortium is to deliver large-scale SARS-CoV-2 genome sequencing capacity to hospitals, regional NHS centres and the Government that, when combined with epidemiological and clinical information, will inform interventions and policy decisions during the current UK COVID-19 epidemic.

The Consortium

CDC, Alissa Ecker/MS and Dan Higgins/MAMS
Computer model of SARS-CoV-2 virus that causes COVID-19
Computer model of SARS-CoV-2 virus that causes COVID-19

The COG-UK Consortium is an innovative partnership of NHS organisations, the four Public Health Agencies of the UK, the Wellcome Sanger Institute and more than 12 academic institutions providing sequencing and analysis capacity.

It is supported by £20 million funding from the UK Department of Health and Social Care (DHSC), UK Research and Innovation (UKRI) and the Wellcome Trust.

For a full list of collaborating organisations, researchers and funders, please see the COG-UK Consortium website

How the Consortium works

Samples from patients with COVID-19 infection are collected by NHS laboratories, Public Health laboratories and national coronavirus Testing Centres as part of their routine diagnostic work. Genome sequencing is performed by a network of regional laboratories which currently includes Belfast, Birmingham, Cambridge, Cardiff, Edinburgh, Exeter, Glasgow, Liverpool, London, Norwich, Nottingham, Oxford and Sheffield, backed up by a national sequencing hub at the Sanger Institute.

Virus genome data are combined with clinical and epidemiological datasets in order to help to guide UK public health interventions and policies. Subsequent analyses will enable evaluation of novel treatments and non-pharmacological interventions on SARS-CoV-2 virus populations and spread, and provide information on introductions versus community transmission and outbreaks. These data will also allow researchers to identify and evaluate emerging genetic changes and understand how they affect the ability of the virus to transmit from person to person, and to cause severe forms of the disease.

COG-UK Aims

  • Understand the national and international epidemiology and spread of the SARS-CoV-2 virus, including monitoring asymptomatic spread in the community.
  • Determine the level of, and routes of, hospital- and healthcare-based (nosocomial) transmission of the virus to support hospital or bed closures and other events.
  • Monitor interventions and their effectiveness in limiting COVID-19 – to understand their impact and guide their use.
  • Determine the potential effect of future treatments, including emergence of resistance to vaccines or therapies by the virus.
  • Understand the biological behaviour of the SARS-CoV-2 virus.
  • Drive the development of advanced research techniques and insights through greater data integration (for example by combining health records, virus genomics, human genomics and metagenomics).
  • Facilitate international collaboration on COVID-19 through open data sharing of UK SARS-CoV-2 sequencing data.
  • In the longer term, build UK-wide capacity for managing major epidemics within the NHS, Public Health Agencies and academic institutions.

How the Sanger Institute contributes to COG-UK

The Sanger Institute has one of the largest sequencing centres in the world, coupled with Europe’s largest biological data centre. It is supplying its world leading expertise in sample logistics, metadata handling, bioinformatic analysis and interpretation to the COG-UK Consortium to enable rapid and standardised sample collection, sequencing, data linkage and visualisation. This is supported by a large team led by Cordelia LangfordIan JohnstonAlex AldertonMatt BerrimanMara LawniczakDavid AanensenJohn SillitoeJohn Danesh and Dominic Kwiatkowski.  Ewan Harrison serves as Project Manager responsible for overall coordination of the COG-UK network.

To see the full list of contributors, please click this link: Wellcome Sanger Institute COVID-19 Surveillance Team.

Providing a national sequencing hub

The Sanger Institute is providing a centralised service for large-scale genome sequencing of samples from the ‘Lighthouse Lab’ National Testing Centres and from other diagnostic services in parts of the UK that are not covered by the COG-UK regional sequencing labs. It also serves as a backup to take pressure off the regional sequencing labs during periods of high demand.

Several teams within the Institute’s Scientific Operations and Scientific Computing facilities are working to deliver and optimise the sequencing production pipeline, supported by faculty and staff from the Parasites and Microbes Programme:

Supporting metadata collection, data integration and data visualisation

Sanger faculty and staff within the Health Data Research UK (HDR UK) consortium are exploring and refining routes by which relevant and insightful information about the people who have been infected can be gathered and attached to the virus’ genome sequence data. These data will enable research into the specific actions of the virus and the groups of people most susceptible to guide future public health protection strategies.

Members of the Centre for Genomic Pathogen Surveillance are deploying their Epicollect5 mobile app to facilitate collection of samples and metadata from NHS testing labs. They are also refining their Data-flo and MicroReact online platforms to generate real-time displays of the transmission and spread of the virus at the national and local level.

Contact

If you need help or have any queries, please contact us using the details below.

Sanger people

A wide range of Sanger Institute researchers, subject matter experts and technicians are contributing to the COG-UK consortium.

Photo of Professor David Aanensen

Professor David Aanensen

Director of the Centre for Genomic Pathogen Surveillance and Group Leader

Photo of Dr Alex Alderton

Dr Alex Alderton

Head of Cellular Operations

Photo of Dr Roberto Amato

Dr Roberto Amato

Senior Staff Scientist

Photo of Dr Matt Berriman

Dr Matt Berriman

Senior Group Leader

Photo of Dr Peter Clapham

Dr Peter Clapham

ISG Team Leader

Photo of Dr Tim Cutts

Dr Tim Cutts

Head of Scientific Computing

Photo of Dr Martin Dougherty

Dr Martin Dougherty

Chief Operating Officer

Photo of Dr Ewan Harrison

Dr Ewan Harrison

Career Development Fellow

Photo of Professor Dominic Kwiatkowski

Professor Dominic Kwiatkowski

Head of Parasites and Microbes Programme and Senior Group Leader

Photo of Dr Cordelia Langford, FRSB

Dr Cordelia Langford, FRSB

Director of Science Operations

Photo of Dr Mara Lawniczak

Dr Mara Lawniczak

Group Leader

Photo of Rich James Livett

Rich James Livett

Production Software Developer Team Leader

Photo of Dr Rachel Nelson

Dr Rachel Nelson

Head of CGaP, Cellular Generation & Phenotyping Core Facility

Photo of Dr Christoph Puethe

Dr Christoph Puethe

Senior Scientific Manager

Photo of Professor Sir Mike Stratton, FMedSci  FRS

Professor Sir Mike Stratton, FMedSci FRS

Director of the Wellcome Sanger Institute and Chief Executive Officer of the Wellcome Genome Campus

External partners and funders

External

Funder: UK Research and Innovation (UKRI)

UKRI works in partnership with universities, research organisations, businesses, charities, and government to create the best possible environment for research and innovation to flourish. We aim to maximise the contribution of each of our component parts, working individually and collectively. We work with our many partners to benefit everyone through knowledge, talent and ideas. Operating across the whole of the UK with a combined budget of more than £7 billion, UK Research and Innovation brings together the seven research councils, Innovate UK and Research England.

External

Funder: Wellcome

Wellcome exists to improve health by helping great ideas to thrive. We support researchers, we take on big health challenges, we campaign for better science, and we help everyone get involved with science and health research. We are a politically and financially independent foundation.

External

Partner: Belfast Health and Social Care Trust

The Belfast Health and Social Care Trust (BHSCT) Regional Virus Laboratory team are working in partnership with Queen’s University Belfast and BHSCT Regional Genetics Laboratory to sequence SARS-CoV-2 samples from patients in Northern Ireland as part of the COG-UK consortium.

External

Partner: Cardiff University

The Cardiff University team are supporting the project through the use of the MRC CLIMB node hosted at Cardiff, which will provide computational capacity for analysis and data storage for the consortium. The bioinformatics and sequencing staff in the School of Biosciences are also working as part of the PHW Pathogen Genomics effort to manage, sequence and analyse SARS-COV-2 samples collected in Wales.

External

Partner: Genomics Partnership Wales

Genomics Partnership Wales (GPW) is the entity setup by Welsh Government to deliver the Welsh Genomics for Precision Medicine Strategy. GPW is the umbrella for pathogen and human genomics work in the NHS in Wales, and is supporting the Pathogen Genomics work being undertaken in Wales.

External

Partner: MRC-University of Glasgow Centre for Virus Research

The mission of the MRC-Centre for Virus research is to carry out fundamental research on viruses and viral diseases, translating the knowledge gained for the improvement of health and the benefit of society.

External

Partner: West of Scotland Specialist Virology Centre, NHS Greater Glasgow and Clyde

The West of Scotland Specialist Virology Centre is working with the MRC-University of Glasgow Centre for Virus Research.

External

Partner: Public Health England

Public Health England aims to address urgent threats to health in the 21st century. The organisation has been central to the national response to COVID-19, and has led this proposal to develop a national capability to sequence the causative virus and use this to inform public health interventions. The COVID-19 Genomics UK (COG-UK) Consortium will be led by Sharon Peacock as a collaborative initiative to capture information on the virus and from patients so as to reduce the impact from the COVID-19 epidemic in the UK. 

External

Partner: Public Health Wales NHS Trust

Public Health Wales NHS Trust (PHW) is the national public health authority for Wales. PHW works to protect and improve health and well-being and reduce health inequalities for the people of Wales. PHW is leading the national response to COVID-19 in Wales. PHW operates diagnostic laboratories across Wales and has been providing SARS-COV-2 testing in Wales. In addition, PHW epidemiology teams have been providing support across Wales to track cases and support management of the outbreak. Sequencing of Welsh samples is being undertaken by the Pathogen Genomics Unit (PenGU). PenGU was formally launched in 2018, and provides an accredited sequencing environment for a range of clinical pathogen genomics services for the whole of Wales. The Pathogen Genomics team in Public Health Wales will be contributing to COG-UK by sequencing and analysing Welsh SARS-COV-2 cases. Data that is being generated is being fed back in real time to clinical colleagues across the NHS in Wales as well as feeding into outbreak management and planning within the Welsh NHS and Welsh Government. In addition to sequencing samples, the team are providing bioinformatics support to build production-ready pipelines for processing samples, supporting the development of systems on CLIMB for consortium use and leading efforts to enable metadata sharing across the UK.

External

Partner: University College London

The UCL team have been working in joint partnership with Virology at Imperial College Healthcare NHS Trust; Dr David Muir and Dr Paul Rendell to deliver the pipeline of sequencing data. UCL and Imperial are also leading the COG-UK Hospital-Onset COVID-19 Infections (HOCI) Study; A phase III prospective, interventional, cohort, superiority study to evaluate the benefit of rapid COVID-19 genomic sequencing (the COVID-19 GENOMICS UK project) on infection control in preventing the spread of the virus in United Kingdom NHS hospitals. COG-UK collaborators include Glasgow, Sheffield and Guys and St Thomas’ Trust.

External

Partner: University of Birmingham

The University of Birmingham team will be drawing on ARTIC and CLIMB. The CLIMB project, which recently secured funding for a further five years with the CLIMB-BIG-DATA project, will provide the data analysis pipelines, computing and storage capacity required. The ARTIC project, funded by a Wellcome Trust Collaborative Award, is a collaborative project to put genomics at the heart of outbreak response.

External

Partner: University of Exeter

The University of Exeter team is working closely with the Clinical Diagnostics teams at the Royal Devon and Exeter NHS Trust and in the surrounding area.

External

University of Northumbria

The DNA sequencing research facility at Northumbria University, NU-OMICS, is linked to both academic and industrially linked DNA sequencing projects.

External

Partner: University of Nottingham

The University of Nottingham team is working closely with the Clinical Pathology team at Nottingham University Hospitals. The University of Nottingham next generation sequencing platform, DeepSeq, is providing sequencing expertise and the Virology groups are helping support access to samples.

External

Partner: University of Portsmouth

The University of Portsmouth Team are currently working in partnership with Portsmouth Hospitals NHS Trust.

External

Partner: University of Sheffield

The University of Sheffield team is working in partnership with the Sheffield Teaching Hospitals NHS Foundation Trust’s regional NHS virology laboratory based at the Northern General Hospital.

Related groups

The following teams are contributing members to the consortium's work

Connect with us on Twitter

NEWS: Analysis of #COVID19 genomes reveals large numbers of introductions to the UK in March.

Read more 👉 https://www.bdi.ox.ac.uk/news/analysis-of-covid-19-genomes-reveals-large-numbers-of-introductions-to-the-uk-in-march

@sangerinstitute @CovidGenomicsUK @TheCGPS

*Update* to COVID-19 ARTIC v3 Illumina library construction and sequencing protocol @sangerinstitute. A change in annealing temperature from 65°C to 63°C recovers amplicon 64 dropout and reduces variation in coverage. @CovidGenomicsUK http://dx.doi.org/10.17504/protocols.io.bgq3jvyn